Business● LowSep 8 · Sep 8, 2026, 8:33 AM
Upstream Bio stock jumps 8% on Phase 2 severe asthma data
GlobeAlert Desk · curated from Seeking Alpha Tech · global
Upstream Bio's stock increased by 8% following the release of Phase 2 data related to severe asthma treatment. This indicates a positive market reaction to the clinical trial results.
GlobeAlert aggregates and classifies open sources; the story above belongs to its publisher. Summaries are machine-generated from the source text. How we score stories.
GlobeAlert context
What the desk knows about this story
Threat level
0 Low
Scored from severity, scale, escalation potential and source agreement. Below the alert threshold.
Sources
1 publisher
Single-source so far. Treat details as unconfirmed until more publishers report.
Category
Business
Not flagged as developing.
More in Business
Business27m agoSullivan: What the 2026 midterms could mean for energy investorsCNBCBusiness29m agoTamil Nadu government releases three-year BESS policyThe HinduBusiness30m agoAIRO Group offers upside as military drone demand accelerates: Roth CapitalSeeking Alpha TechBusiness30m agoIbotta rallies on Q3 results; Goldman removes Sell ratingSeeking Alpha Tech